Laboratory Monitoring of Cyclosporine Pre-dose Concentration (C 0) after Kidney Transplantation in Isfahan

Iranian Journal of Medical Sciences

Volumn 28, Issue 2, 2003, Pages 81-85

  Tolou Ghamari, Z ^a   Palizban, A A ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cyclosporine; Kidney transplantation; Laboratories

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CHILD; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRAN; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; RADIOIMMUNOASSAY; SIDE EFFECT;

EID: 0345600195     PISSN: 02530716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kahan BD: The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring. Therapeutic Drug Monitoring. 1995;17(6):560-3.
2. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al: Cyclosporine pharmacokinetics in renal transplant recipients. Clin Pharmacol Ther. 1985;38(3):296-303.
3. Tsunoda SM, Aweeka FT: The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996;30(2): 107-40.
4. Andany MA, Kasiske BL: Care of the kidney transplant recipient. Vigilant monitoring creates the best outcome. Postgrad Med 2002; 112(3):93-6, 101-2, 105-8 passim.
5. Kahan BD, Welsh M, Schoenberg L, et al: Variable absorption of cyclosporine. Transplantation 1996; 62(5): 599-606.
6. Trull AK, Tan KK, Tan L, et al: Absorption of cyclosporine from conventional and new microemulsion oral formulations in liver transplant recipients with external bile diversion. Br J Clin Pharmacol 1995; 39(6): 627-631.
7. Fahr A: Cyclosporine clinical pharmacokinetics. Clin Pharmacokinet. 1993; 24(6):472-95.
8. Akhlaghi F, Trull AK: Distribution of cyclosporine in organ transplant recipients. Clin Pharmacokinet. 2002; 41(9):615-37.
9. Sewing KF, Christians U, Kohlhaw K, et al: Biologic activity of cyclosporinee metabolites. Transplant Proc 1990; 22(3): 1129-34.
10. Christians U, Bleck JS, Lampen A, et al: Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporinee metabolite patterns in stable male and female renal allograft recipients after co-administration of renal allograft recipients after co-administration of diltiazem? Transplant Proc 1996; 28(4): 2159-61.
11. Canafax DM: Minimizing cyclosporinee concentration variability to optimise transplant outcome. Clin Transplant 1995; 9(1): 1-13.
12. Tolou-Ghamari Z: Monitoring tacrolimus in liver transplant recipients: a consideration of alternative techniques and the influence of clinical status. PhD thesis 1999; University of London.
13. Inoue S, Beck Y, Nagao T, Uchida H: Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants. Transplant Proc 1994;26(5):2571-3.
14. Min DI, Perry PJ, Chen HY, et al: Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy 1998; 18(2): 282-7.
15. Bock HA, Kamber V, Brunner FP, et al: Weight-independent dosing of cyclosporine-an alternative to the "mg/kg" doctrine. Transplantation 1994;57(10):1484-9.
16. Gjertson DW: Impact of delayed graft function and acute rejection on graft survival. Transplant Proc 2002;34(6):2432.
17. Ohlman S, Lindholm A, Hagglund H, et al: On the intraindividual variability and chronobiology of cyclosporinee pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993;44(3):265-9.
18. Lindholm A, Kahan BD: Influence of cyclosporine pharmacokinetics, trough concentration and AUC monitoring on outcome of kidney transplantation. Clin Pharmacol Ther 1993; 54(2): 205-18.
19. Tolou_Ghamari Z, Wendon J, Tredger JM: In-vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation. Clin Chem Lab Med 2000;38(11): 1209-11.
20. Salomon D, Brunson M, Vansickler J, et al: A retrospective analysis of late renal graft function: correlation with mean cyclosporine levels and lack of evidence for chronic cyclosporinee toxicity. Transplant Proc 1991;23(1pt2):1018-9.
21. Tan KK, Trull AK, Hue KL, et al: Pharmacokinetics of cyclosporine in heart and lung transplantation candidates and recipients with cycstic fibrosis and Eisenmeenger's syndrome. Clin Pharmacol Ther 1993;53(5): 544-54.
22. Batiuk TD, Pazderka F, Enns J, et al: Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995;96(3): 1254-60.
23. Lindholm A: Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991;13(6): 465-77.